Caplin Point Laboratories Limited (CAPLIPOINT)

Healthcare · Pharmaceuticals & Biotechnology · NSE · Updated 16 July 2026

₹2,671.5 ↑ 28.48% (1Y)

🎯 Key Takeaways

Caplin Point Laboratories is in a high-growth phase driven by strategic expansion into regulated international markets and significant capex investment in complex API manufacturing. Management is actively building a global footprint in the US, Latin America, Canada, and Australia, supported by robust financial performance and a disciplined capital allocation strategy.
Revenue grew 2% QoQ to ₹493 in Q3FY25.
⚠️ Execution risk in scaling new facilities in Puducherry, Visakhapatnam, and Chennai on schedule and within budget.

Market Cap

₹15,193

P/E Ratio

29.5

Div Yield

0.00%

Promoter

0.0%

✨ Ask AI About CAPLIPOINT 📊 Interactive Charts

📖 The Story

Caplin Point Laboratories is in a high-growth phase driven by strategic expansion into regulated international markets and significant capex investment in complex API manufacturing. Management is actively building a global footprint in the US, Latin America, Canada, and Australia, supported by robust financial performance and a disciplined capital allocation strategy.

📰 What's Happening

In the latest filing on May 14, 2026, the company announced an interim dividend of INR 4 per share (200% payout) with a record date of May 30, 2026, following the release of audited FY26 financials showing ₹2,303 crores in revenue and ₹650 crores in net profit. Management highlighted ongoing capex of ₹1,000+ crores for new facilities in Puducherry, Visakhapatnam, and Chennai focused on lyophilized injectables and oncology APIs. The company also disclosed plans for DMF filings by end of FY27 and expansion into Canada, Australia, Mexico, and Brazil markets. A conference call on May 14, 2026, was scheduled to discuss FY26 results and future outlook, with trading window closure preceding result finalization in late June 2026.

Source: Stock Announcements

📊 Quarterly Results (₹ Cr)

Metric	Q4FY23	Q1FY24	Q2FY24	Q3FY24	Q4FY24	Q1FY25	Q2FY25	Q3FY25
Revenue	389	395	410	436	453	459	483	493
Operating Profit	135	139	158	159	163	170	186	194
OPM %	31.8%	32.0%	33.5%	32.7%	32.0%	33.1%	34.1%	32.9%
Net Profit	101	104	116	120	121	125	131	140
EPS	₹13.45	₹13.62	₹15.13	₹15.44	₹16.01	₹16.32	₹17.22	₹18.28

Revenue and profitability have shown consistent growth over the past four quarters, with Q3FY25 revenue at ₹493 crores and net profit at ₹140 crores, reflecting a sustained upward trend in operational performance. The company has maintained stable operating margins around 33% despite scaling up, indicating efficient cost management. This growth trajectory aligns with management’s disclosed investments in high-value segments and expansion into regulated markets, which they expect to drive margin-accretive scale over the next 2-3 years.

🔮 Management Outlook & What's Next

Management has outlined an ambitious global expansion strategy, targeting DMF filings for 90+ APIs by end of FY27 and entry into Canada, Australia, Mexico, and Brazil markets. They have emphasized that the recent capex allocation is aimed at strengthening manufacturing capabilities for complex products like lyophilized injectables and oncology APIs, which are expected to enhance pricing power and margin resilience in regulated markets.

Extracted from official company announcements. Not StockFin.ai's opinion.

⚖️ Peer Comparison — Pharmaceuticals & Biotechnology

Company	MCap (₹ Cr)	P/E	ROCE	ROE	D/E
Sun Pharmaceutical Industries Limited	4.51 L Cr	41.3	20.3%	15.1%	0.03
Divi's Laboratories Limited	1.79 L Cr	72.4	22.1%	16.6%	0.00
Torrent Pharmaceuticals Limited	1.49 L Cr	80.1	—	—	—
Cipla Limited	1.16 L Cr	25.4	19.4%	14.6%	0.00
Dr. Reddy's Laboratories Limited	1.12 L Cr	20.0	19.7%	16.6%	0.12
Lupin Limited	1.04 L Cr	36.2	—	—	—
Mankind Pharma Limited	1.03 L Cr	49.2	—	—	—
Zydus Lifesciences Limited	1.02 L Cr	22.5	—	—	—
Aurobindo Pharma Limited	87,806	25.3	—	—	—
Laurus Labs Limited	71,455	356.8	—	—	—

🔗 Peer Stock Analyses

SUNPHARMA DIVISLAB TORNTPHARM CIPLA DRREDDY

⚠️ Risk Factors

1. Execution risk in scaling new facilities in Puducherry, Visakhapatnam, and Chennai on schedule and within budget. 2. Regulatory and compliance risks associated with entering highly regulated markets like the US and Canada, where approval timelines and quality audits can delay revenue generation. 3. Customer concentration risk in export markets, which could impact order visibility and revenue predictability.

📋 Recent Filings

🧠 Analyst's Read

Caplin Point Laboratories is transitioning from a domestic-focused manufacturer to a globally integrated player with a clear strategy in complex generics and high-barrier-to-entry products. The next 12–18 months will be critical in validating its international expansion and DMF filing success, making regulatory progress and order realization in new markets key near-term catalysts to watch.

Based on filing content and financial data. Not a recommendation.

Read the full analysis

Quarterly trends, balance sheet, cash flow, peer comparison, and AI insights — sign up free to unlock.

2 free AI queries per day.

✨ Deep Dive with AI on CAPLIPOINT

Data sourced from stock announcements. Analysis generated by StockFin.ai.
For informational purposes only — not investment advice. Updated 2026-07-16.

📡 Get AI alerts when CAPLIPOINT files new disclosures

Track CAPLIPOINT filings, board meetings, and corporate actions. Free email alerts at 5 PM.

Track CAPLIPOINT — Free

Free account · 2 AI queries/day